Because of the recalcitrance of some micropollutants to conventional wastewater treatment systems, the occurrence of organic micropollutants in water has become a worldwide issue, and an increasing environmental concern. Their biodegradation during wastewater treatments could be an interesting and low cost alternative to conventional physical and chemical processes. This paper provides a review of the organic micropollutants removal efficiency from wastewaters. It analyses different biological processes, from conventional ones, to new hybrid ones. Micropollutant removals appear to be compound- and process- dependent, for all investigated processes. The influence of the main physico-chemical parameters is discussed, as well as the removal efficiency of different microorganisms such as bacteria or white rot fungi, and the role of their specific enzymes. Even though some hybrid processes show promising micropollutant removals, further studies are needed to optimize these water treatment processes, in particular in terms of technical and economical competitiveness.

Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, atopic dermatitis and nasal polyposis, but their function in human cancer remains unclear. Here we show that, in acute promyelocytic leukaemia (APL), ILC2s are increased and hyper-activated through the interaction of CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6, respectively. ILC2s, in turn, activate monocytic myeloid-derived suppressor cells (M-MDSCs) via IL-13 secretion. Upon treating APL with all-trans retinoic acid and achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored. Similarly, disruption of this tumour immunosuppressive axis by specifically blocking PGD2, IL-13 and NKp30 partially restores ILC2 and M-MDSC levels and results in increased survival. Thus, using APL as a model, we uncover a tolerogenic pathway that may represent a relevant immunosuppressive, therapeutic targetable, mechanism operating in various human tumour types, as supported by our observations in prostate cancer.